Concentrate comprising a p-phenylenediamine derivative

Information

  • Patent Grant
  • 6468723
  • Patent Number
    6,468,723
  • Date Filed
    Monday, May 14, 2001
    23 years ago
  • Date Issued
    Tuesday, October 22, 2002
    21 years ago
Abstract
A concentrated aqueous solution of a p-phenylenediamine derivative, which a) has a pH higher than 12.5, b) contains 0.4 to 1.1 mol p-phenylenediamine derivative/litre, c) contains 0.05 to 2 mol of an antioxidant/litre, d) contains at most 35% by weight of organic solvents with respect to the total solution, e) contains at most 50 mmol sulphate ions/litre and f) is single-phase, is suitable for the production of different colour developer formulations.
Description




This invention relates to a concentrated solution of p-phenylenediamine derivatives, e.g. of N-(2-methylsulphonylaminoethyl)-N-ethyl-3-methyl-p-phenylenediamine (CD-3) and of N-(2-hydroxyethyl)-N-ethyl-3-methyl-p-phenylenediamine (CD-4).




p-phenylenediamine derivatives, particularly the aforementioned compounds CD-3 and CD-4, are known developer substances for colour photographic silver halide materials. They are normally used as a concentrated solution in sulphuric acid. This acidic solution is very stable due to a small addition of sulphite. The free bases of p-phenylenediamine derivatives are very susceptible to oxidation, however, both in solution and in solid form.




If a sulphuric acid concentrate of p-phenylenediamine derivatives is neutralised with alkali hydroxides, precipitates are formed in the concentrate.




For use in one-part colour developer concentrates, however, neutralisation is absolutely necessary, since colour development only occurs under alkaline conditions. Therefore, the colour developer concentrate already has to be alkaline. In order to produce different colour developer formulations, there is therefore a need for a stable, alkaline p-phenylenediamine derivative which can be used universally.




The present invention thus relates to a concentrated, aqueous solution of a p-phenylenediamine derivative, characterised in that it




a) has a pH higher than 12.5,




b) contains 0.4 to 1.1 mol p-phenylenediamine derivative/litre,




c) contains 0.05 to 2 mol of an antioxidant/litre,




d) contains at most 35 % by weight of organic solvents with respect to the total solution,




e) contains at most 50 mmol sulphate ions/litre and




f) is single-phase.




The pH is preferably higher than 13.




This concentrated solution can be produced from the free base or from salts of the respective p-phenylenediamine derivative.




Examples of salts of the p-phenylenediamine derivative which can be used include phosphates, chlorides and sulphates. When sulphates are used, the sulphate is separated off, e.g. as an alkali sulphate (as described in EP 0 980 024, paragraph 58).




EP 0 980 024 describes a concentrated alkaline CD-3 solution which contains an antioxidant and which is low in sulphate. This concentrated solution consists of two phases. Phase separation is only suppressed if large amounts of ethylene glycol are added. A two-phase concentrate is unsuitable for the produktion of a colour developer concentrate.




Suitable water-soluble organic solvents include those from the series comprising glycols, polyglycols, alkanolamines, aliphatic and heterocyclic carbonamides, and aliphatic and cyclic monoalcohols.




Examples of suitable water-soluble solvents include derivatives of carboxylic acid amides and derivatives of urea such as dimethylformamide, methylacetamide, dimethylacetamide, N,N′-dimethylurea, tetramethylurea, methanesulphonic acid amide, dimethylethylene-urea, N-acetylglycine, N-valeramide, isovaleramide, N-butyramide, N,N-dimethylbutyramide, N-(2-hydroxyphenyl)-acetamide, N-(2-meth-oxyphenyl)-acetamide, 2-pyrrolidinone, ε-caprolactam, acetanilide, benzamide toluenesulphonic acid amide, phthalimide;




aliphatic and cyclic alcohols e.g. isopropanol, tert.-butyl alcohol, cyclohexanol, cyclohexane-methanol, 1,4-cyclohexanedimethanol;




aliphatic and cyclic polyalcohols, e.g. glycols, polyglycols, polymer waxes, tri-methyl-1,6-hexanediol, glycerol, 1,1,1-trimethylolpropane, pentaerythritol, sorbitol;




aliphatic and cyclic ketones, e.g. acetone, ethyl methyl ketone, ethyl ketone, tert.-butyl methyl ketone, diisobutyl ketone, acetylacetone, acetonylacetone, cyclo-pentanone, acetophenone;




esters of aliphatic and cyclic carboxylic acids, e.g. triethoxymethane, methyl acetate, allyl acetate, methyl glycol acetate, ethylene glycol diacetate, glycerol-l-acetate, glycerol diacetate, methylcyclohexyl acetate, methyl salicylate, phenyl salicylate;




aliphatic and cyclic esters of phosphonic acid, e.g. methylphosphonic acid dimethyl ester, allylphosphonic acid diethyl ester;




aliphatic and cyclic oxyalcohols, e.g. 4-hydroxy-4-methyl-2-pentanone, salicyl-aldehyde;




aliphatic and cyclic aldehydes, e.g. acetaldehyde, propanal, trimethylacetaldehyde, crotonaldehyde, glutaraldehyde, 1,2.5,6-tetrahydrobenzaldehyde, benzaldehyde, benzene-propane, terephthalaldehyde;




aliphatic and cyclic oximes, e.g. butanone oxime, cyclohexanone oxime;




aliphatic and cyclic amines (primary, secondary or tertiary), e.g. ethylamine, diethyl-amine, triethylamine, dipropylamine, pyrrolidine, morpholine, 2-amino-pyrimidine;




aliphatic and cyclic polyamines (primary, secondary or tertiary), e.g. ethylene-diamine, 1-amino-2-diethylaminoethane, methyl-bis-(2-methylamino-ethyl)amine, permethyldiethylenetriamine, 1,4-cyclohexanediamine, 1,4-benzene-diamine;




aliphatic and cyclic hydroxyamines, e.g. ethanolamine, 2-methylethylamine, 2-methylaminoethanol, 2-(dimethylamino)ethanol, 2-(2-dim ethylamino-ethoxy)-ethanol, diethanolamine, N-methyldiethanolamine, triethanolamine, 2-(2-aminoethyl- amino)-ethanol, triisopropanolamine, 2-amino-2-hydroxymethyl-1,3-propanediol, 1-piperidine-ethanol, 2-aminophenol, barbituric acid, 2-(4-aminophenoxy)-ethanol, 5-amino-l-naphthol.




Suitable antioxidants are compounds of formulae (I), (II) and (III).











wherein




R


1


denotes an alkyl which is optionally substituted,




R


2


denotes an alkyl which is optionally substituted or an aryl which is optionally substituted, and




n denotes 0 or 1,




preferably those in which at least one of the R


1


and R


2


radicals contains at least one —OH, —COOH or —SO


3


H group;











wherein




R


3


denotes an alkyl or acyl group;











wherein




R


4


denotes an alkylene group which is optionally interrupted by 0 atoms, and




m denotes a number of at least 2.




In addition to the aforementioned types of substitution, the alkyl groups R


1


, R


2


, R


3


, the alkylene group R


4


and the aryl group R


2


can also contain other substituents.




Examples of suitable antioxidants include











The preferred solvents are alcohols, glycols, polyglycols and caprolactam, and optionally mixtures thereof also. Preferred p-phenylenediamine derivatives are listed in EP 0 980 024, paragraph 28.











EXAMPLES




Example 1 (comparison)





















deionised water




500 ml







aqueous potassium hydroxide solution,




100 ml







45% by weight







diethylhydroxylamine, 85% by weight




200 ml







CD 3 base




190 g







made up to 1000 ml with deionised water







pH 11.5













CD 3 was precipitated from this single-phase solution after







a short period of time.















Example 2 (comparison)





















deionised water




700 ml







aqueous potassium hydroxide solution




150 ml







45% by weight







HADS




150 g







CD 3 base




190 g







made up to 1000 ml with deionised water







pH 11.5













CD 3 was precipitated from this single-phase solution after







a short period of time.















Example 3 (invention)





















deionised water




300 ml







aqueous potassium hydroxide solution,




300 ml







45% by weight







diethylhydroxylamine, 85% by weight




200 ml







CD 3 base




190 g







made up to 1000 ml with deionised water







pH 14













No precipitate was formed from this single-phase solution,







even after a long period of time.















Example 4 (invention)





















deionised water




400 ml







aqueous potassium hydroxide solution,




350 ml







45% by weight







HADS




150 g







CD 3 base




190 g







made up to 1000 ml with deionised water







pH 14













No precipitate was formed from this single-phase solution,







even after a long period of time.















Example 5 (invention)





















deionised water




200 ml







aqueous potassium hydroxide solution,




360 ml







45% by weight







diethylhydroxylamine, 85% by weight




200 ml







CD 3 phosphate




220 g







made up to 1000 ml with deionised water







pH 14













No precipitate was formed from this single-phase solution,







even after a long period of time.















Example 6 (invention)





















deionised water




200 ml







aqueous potassium hydroxide solution,




400 ml







45% by weight







diethylhydroxylamine, 85% by weight




200 ml







CD 3 sulphate




300 g







diethylene glycol




100 ml







made up to 1000 ml with deionised water







pH 14















Potassium sulphate, the solubility of which was low, was even precipitated during the dissolution of CD 3. In order to complete this precipitation, the batch was allowed to stand for one day whilst being cooled to minus 10C. The precipitated potassium sulphate was separated from the supernatant solution. The filtrate was a single-phase solution which was low in sulphate and from which nothing was precipitated even after a long period of time.




At a sufficiently high pH (Examples 3 to 6), the single-phase, low-sulphate concentrates remained stable.



Claims
  • 1. A concentrated aqueous solution of a p-phenylenediamine derivative, which comprisesa) has a pH higher that 12.5, b) contains 0.4 to 1.1 mol p-phenylenediamine derivative/litre, c) contains 0.5 to 2 mol of an antioxidant/litre, d) contains at most 35% by weight of organic solvents with respect to the total solution, e) contains at most 50 mmol sulphate ions/litre and f) is single-phase.
  • 2. The concentrated aqueous solution according to claim 1, wherein said antioxidant corresponds to one of formulae (I), (II) and (III) whereinR1 denotes an alkyl which is optionally substituted, R2 denotes an alkyl which is optionally substituted or an aryl which is optionally substituted, and n denotes 0 or 1; whereinR3 denotes an alkyl or acyl group; whereinR4 denotes an alkylene group which is optionally interrupted by O atoms, and m denotes a number of at least 2.
  • 3. The concentrated aqueous solution according to claim 1, wherein the p-phenylenediamine derivative is N-(2-methylsulphonylamino ethyl)-N-ethyl-3-methyl-p-phenylenediamine or N-(2-hydroxyethyl)-N-ethyl-3-methyl-p-phenylenediamine.
  • 4. The concentrated aqueous solution according to claim 1, wherein the antioxidant is diethylhydroxylamine or di-(2-sulphoethyl)-hydroxylamine.
  • 5. The concentrated aqueous solution according to claim 1, which further contains up to 0.5 mol sulphite/litre or up to 0.5 mol hydroxylamine/litre as an additional antioxidant.
  • 6. The concentrated aqueous solution according to claim 1, wherein said organic solvents are water-soluble organic solvents.
  • 7. A process for the production of one-part color developer concentrates which comprises neutralizing the concentrated aqueous solution according to claim 1.
  • 8. A one-part color developer concentrate which comprises the concentrated aqueous solution according to claim 1.
  • 9. The concentrated aqueous solution according to claim 1, wherein formula (I) is present and at least one of the radicals R1 and R2 contain —OH, —COOH or —SO3H group.
  • 10. The concentrated aqueous solution according to claim 1, wherein said antioxidant is selected from the formula consisting of
  • 11. The concentrated aqueous solution according to claim 1, wherein said organic solvent is alcohol, glycol, polyglycol or caprolactam or mixtures thereof.
Priority Claims (1)
Number Date Country Kind
100 24 263 May 2000 DE
US Referenced Citations (4)
Number Name Date Kind
3816134 Schellenberg et al. Jun 1974 A
4298681 Bulloch et al. Nov 1981 A
6017687 Darmon et al. Jan 2000 A
6077651 Darmon et al. Jun 2000 A
Foreign Referenced Citations (3)
Number Date Country
10333302 Dec 1998 JP
11194462 Jul 1999 JP
980 024 Feb 2000 JP